Brutalist Biotech
Max
3
|
5
|
10
|
20
items per feed.
Cutting-edge Biotech news: Presented the old-fashioned way.
Fierce Biotech
FDA rejects Replimune’s melanoma prospect for second time
(1d)
China’s Oricell raises $100M for carcinoma CAR-T plans ahead of IPO push
(1d)
Chutes & Ladders—Former TreeFrog CEO leaps to Orano Med
(2d)
Philips recalls Trilogy Evo ventilator software, warns of ‘under-delivery’ of therapy
(2d)
Boehringer hands over funding, marketing rights for Click’s digital therapeutic
(2d)
Gilead pays Kymera $45M to glue preclinical protein degrader onto burgeoning oncology pipeline
(2d)
J&J launches latest version of its pulsed ablation device after nabbing CE Mark
(2d)
Avalyn plans IPO to fund phase 3 trials of inhaled versions of approved respiratory drugs
(2d)
Judge rules that HHS must face states' lawsuit over RFK Jr.'s agency overhaul, massive layoffs
(3d)
In a first, a CAR-T cell therapy drives 3 autoimmune diseases into remission in a single patient
(3d)
BioPharma Dive
FDA again spurns Replimune melanoma drug
(1d)
Oricell closes a ‘pre-IPO’ megaround to aim CAR-T at solid tumors
(1d)
RFK Jr. rewrites ACIP rules; Gilead, Roche dig into protein degraders
(1d)
Women have awaited a revolution in menopause. It hasn’t arrived.
(1d)
Invivyd reveals plans to test an antibody drug against measles
(2d)
Chasing a tough-to-treat lung disease, Avalyn plans an IPO
(2d)
Lilly launches GLP-1 pill, kicking off showdown with Novo Nordisk
(2d)
Sidewinder secures $137M to advance ‘precision’ ADCs
(3d)
With 3 quick buyouts, Gilead leans into its latest transformation
(3d)
Activist investor revives campaign to overhaul Novavax board
(3d)
Endpoints News
More pharma dealmaking; FDA’s proposed budget; Takeda ends partnership; and more
(10h)
Plan for remade ACIP panel adds focus on vaccine safety, matching Kennedy’s push
(1d)
Bayer pharma executive predicts US-Europe price spreads will narrow
(1d)
FDA rejects Replimune cancer therapy, saying company didn't resolve trial doubts
(1d)
China biotech’s CRISPR therapy suggests US drugmakers will face competition
(1d)
Vivatides gets $54M; Wegovy drops cold chain in EU; Gilead takes Kymera option
(1d)
Biotech VCs ramp up checks on new bets after years of focusing on existing portfolios
(1d)
Novo's double departures: As GLP-1 luminary retires, an obesity leader goes to Boehringer Ingelheim
(1d)
China-based CAR-T company Oricell raises $40M more as it looks to go public
(1d)
FDA plans another safety study of abortion drug after court order
(2d)
BioSpace
Replimune’s advanced melanoma drug rebuffed by FDA for second time
(1d)
With oral obesity race underway, all eyes are on Lilly’s Foundayo launch
(1d)
For AI To Have Impact, the Industry Must Align on Data
(1d)
GSK again pulls application for leucovorin, touted by FDA as potential autism treatment
(1d)
FDA probes pregnancy pill anew after court keeps mail access alive
(1d)
FDA probes abortion pill anew after court keeps mail access alive
(1d)
Innovent’s CDMO gets green light to make biologics at large Chinese plant
(2d)
Roche sticks with C4T, adding up to $1B for molecular glue partnership
(2d)
Report: Biopharma Job Market Report Q1 2026
(2d)
Novartis-backed Sidewinder collects $137M series B to strike at difficult-to-treat tumors
(2d)
STAT News
What STAT readers think about nutrition education in med school
(9h)
Sports betting is creating a twofold public health crisis for some young men
(9h)
GAO report shows gap between scale of illegal vapes and enforcement
(1d)
Replimune skin cancer drug that became FDA flashpoint is rejected again
(1d)
Up and down the ladder: The latest comings and goings
(1d)
Trump administration admits a glaring error in its accusations about New York health care fraud
(1d)
A new trick for old science, and biotech VCs’ scrambled playbook
(1d)
We’re reading about cheap generic obesity drugs in India, high demand for estrogen patches and more
(1d)
GSK says goodbye to leucovorin (again)
(1d)
How sports betting apps hook users
(1d)
BioPharma Trend
Life Biosciences Gets $80M as Cellular Rejuvenation Enters the Clinic
(2d)
Jeito Closes €1B Fund, Europe's Largest Independent Biopharma Raise
(2d)
Anthropic Pays $400M for an AI Biotech With Fewer Than Ten People
(4d)
Epia Neuro Wants to Decode Brain's Movement Intentions After Stroke
(1w)
Generare Raises €20M to Explore Uncharacterized Chemical Space from Microbial DNA
(1w)
Enveda’s AI-Discovered Drug Shows Early Atopic Dermatitis Relief
(2w)
Lilly Signs $2.75B AI Drug Discovery Deal With Insilico
(2w)
Meta Open Sources Foundation Model That Predicts Brain Responses to Speech, Video, and Text
(2w)
Two Ex-GSK AI Leads Go Stealth with a New Oncology Drug Discovery Startup
(2w)
Tempus and Daiichi Sankyo Partner on AI-Guided Cancer Biomarker Discovery
(2w)
Drug Channels
The Net Pricing Revolution in the Drug Channel: What’s Deflating the Gross-to-Net Bubble (rerun)
(1d)
The FTC Blows Up Express Scripts’ PBM Model—and Launches the Net Pricing Drug Channel (rerun)
(2d)
List Price Reductions Will Deflate the Gross-to-Net Bubble–and Threaten Pharmacy and 340B Profits from IRA-Negotiated Drugs (rerun)
(3d)
Drug Channels News Roundup, Mid-April 2026: Vertical Integration & MLR Games, Copay Maximizers, Hospital Price Chaos, and One Big Drug Channel Family
(4d)
The Big Three PBMs’ 2026 Formulary Exclusions: MFP, Private Label Biosimilars, and Direct-to-Patient Threats for PBMs (rerun)
(5d)
Building What’s Next: Join Industry Leaders to Shape Access and Affordability Trends Ahead of Asembia AXS26
(1w)
Drug Channels News Roundup, March 2026: Cigna’s 340B Workaround, Merck’s ARPA Surprise, Walgreens’ Automation Bet, Why Rebates Hurt Patients, and a DCI Team Photo
(2w)
The Top Pharmacy Benefit Managers of 2025: Market Share and Key Industry Developments
(2w)
The Rare Journey Needs a Special Pharmacy Partner
(2w)
Reflections and Photos from the Drug Channels Leadership Forum 2026
(2w)
European Biotechnology Magazine
BioNTech reports promising Phase II data for uterine cancer ADC
(5h)
Basilea lands US$6m CARB X boost for novel antibiotic
(2d)
SLAS Announces the Cohort for Innovation AveNEW at SLAS Europe 2026
(3d)
Jeito Capital raises record US$1.2bn to bankroll European biopharma’s next generation
(3d)
Gilead acquires German ADC specialist Tubulis in US$5bn deal
(4d)
Portugal’s biotech industry is growing up
(5d)
The rollercoaster ride stopps and danish IO Biotech goes bust
(1w)
French AI: 20 million funding for Generare to find better data in nature
(1w)
Lilly moves deeper into sleep medicine with up to $7.8 billion Centessa deal
(1w)
Where Life Science Scales in Basel
(2w)
Drug Hunter
Daraxonrasib (RMC-6236): The 2025 Molecule of the Year
(1d)
relacorilant (CORT125134)
(2d)
More Firepower Per Molecule: Bispecific and Dual-payload ADCs Push for Greater Efficacy
(3d)
TNO155
(4d)
Module 3, Section 2: Quality not Quantity
(5d)
quemliclustat
(6d)
soquelitinib
(1w)
asundexian
(1w)
A Deep Dive into INN Proposed List 134
(1w)
AZD5004
(2w)
Labiotech.EU
Top biotech deals in March 2026
(1d)
Multi-agent AI delivers reliable and scalable insights for single-cell omics
(1d)
Extracellular vesicles: a growing pipeline still searching for validation
(3d)
The biggest biotech funding rounds in March 2026
(3d)
The future of cell & gene therapy: Key trends to watch
(4d)
Nionyx Bio’s kidney gene therapy wins the 2026 BIO-Europe Spring Startup Spotlight
(1w)
Portugal: will the life science sector see upswing amid funding worries?
(1w)
Six biotech companies in Berlin to watch in 2026
(1w)
Next-generation allosteric modulators: A glance at the biotech pipeline in 2026
(2w)
Biotech in New Jersey, seven companies leading the charge
(2w)
Bio IT World
CAS Releases Agentic Tool for Literature Discovery
(1d)
'Mini-brain' Model Explores Concussion's Effects at Cellular Level
(2d)
‘Humble’ AI Reveals When It is Uncertain in Diagnoses
(4d)
Inductive Bio on a Winning Streak With ADMET Predictions
(1w)
From Data to Discovery: Inside the Bio-IT Hackathon
(1w)
Mapping the Trillion-Gene Universe: The Startup That Wants to Teach AI the Language of Life
(2w)
The Value of Prediction, and Cost of Success, in Drug Hunting
(2w)
Follow the Money: Brain-Computer Retinal Implant, Expansion of Alzheimer’s Platform, Migraine Therapies
(2w)
Verily, Samsung Collaborate, Improving AI Trustworthiness, FDA Approval for PathAI
(3w)
PerturbAI Launches with CRISPR Atlas
(3w)
GEN News
Epigenetics at Birth Links Microbiome to Neurodevelopment, Potentially ASD and ADHD
(1d)
First Detailed Insight into Bornavirus Nucleoprotein–RNA Complex Reveals Unique Assembly
(1d)
Cryo-EM Structural Biology Facility Opened in San Diego by FairJourney Bio
(1d)
Drugs from a Text Prompt, Wegovy Pill Competition Dampens Lilly’s Surge
(1d)
Cancer Drug Shortfalls Tied to How BET Inhibitors Hit BRD2 and BRD4 Differently
(1d)
BBB Access Route via Proteomic Vascular Mapping
(2d)
DNA Uptake in Cholera May Increase Defense Mechanisms
(2d)
Seer to Apply Deep Proteomics Tech to Singapore Population Cohort Study
(2d)
Labguru Customer Portal Launched for CRO/CDMO and Client Collaboration
(2d)
Single-Cell Atlas of Maternal–Fetal Interface Sheds Light on Pregnancy Complications
(2d)
Cure Today
Treating Metastatic TNBC: Dr. Hope Rugo on ADCs and Personalized Therapy
(3w)
Understanding High-Risk Essential Thrombocythemia
(3w)
Son’s Decision to Donate Gave His Father a Second Chance
(3w)
Functional Precision Medicine Advances Brain Tumor Care
(3w)
Home-Based Chemotherapy at Mayo Clinic Shows Safe Option for Patients With Cancer
(3w)
Choosing Motherhood Amidst Stage 4 Breast Cancer
(3w)
FDA Approves Opdivo Combo for Newly Diagnosed Advanced Hodgkin Lymphoma
(3w)
How Honest Conversations Strengthened a Couple After Cancer
(3w)
Cardiac Health in Cancer Survivors: A Growing Need
(3w)
Why Open Communication is Crucial for Patients With Multiple Myeloma
(3w)
Contract Pharma
Apotex Gets First US Tentative Approval for Generic Semaglutide Injection
(1d)
Circio Completes Oversubscribed Financing, With Proceeds to Accelerate Circular RNA Platform
(1d)
FairJourney Bio Opens Cryo-Electron Microscopy Structural Biology Facility in San Diego
(1d)
IAOSO Bio Partners with Instituto Butantan to Expand Access to CAR-T Cell Therapy in Brazil
(1d)
Charles River, American Heart Association Partner to Advance Cardiovascular Health Awareness
(1d)
Introducing the Contract Pharma ‘Friday Brief’ — April 10, 2026
(1d)
Altruist Biologics’ Hangzhou Facility Gets First Commercial-Scale Manufacturing License
(2d)
Glenmark Gets FDA Approval for Bioequivalent Progesterone Vaginal Insert
(2d)
Thermo Fisher, Singapore’s PRECISE Partner on Population-Scale Proteomics Biobank
(2d)
Touchlight, SVF Vaccines Partner to Advance Hepatitis B/D Vaccine
(2d)
Pharma Times
Oxford BioTherapeutics signs collaboration with Bristol Myers Squibb
(2d)
Kainova expands DT 7012 trial into Europe
(2d)
Amgen reports positive phase 3 results for subcutaneous TEPEZZA in thyroid eye disease
(4d)
CatalYm begins phase 2b trial of visugromab in second-line liver cancer treatment
(4d)
FDA approves new high dose Spinraza regimen for SMA
(1w)
Viridian reports positive results from elegrobart phase 3 trial
(1w)
Cure Parkinson’s convenes expert panel to assess £2 million combination therapy funding call
(2w)
Kygevvi approved in Europe as first treatment for TK2d
(2w)
Tozorakimab shows significant benefit in two major COPD trials
(2w)
Daratumumab becomes first oncology injectable approved for patient administration
(2w)
Medcity News
How TEFCA Is Speeding Up Disability Benefits Determinations at Hospitals
(22h)
Oricell Lands $110M to Take Cell Therapy to New Territory in Cancer
(23h)
With $100M Raise, Chapter Targets Medicare Mismatches for Seniors
(1d)
Know Your Patient: How Technology Can Help Health Care Providers Dramatically Improve One Key Aspect of the Patient Experience
(1d)
Healthcare’s Most Fixable Cost Problem: Administrative Waste
(1d)
Luminai Raises $38M With Cleveland Clinic Using Its AI for Hospital Operations
(1d)
Which Health Plans Rank Highest In Digital Experience?
(2d)
Gilead and Roche Bet on Protein Degraders for Their Cancer Drug Pipelines
(2d)
AI-Driven Precision Care is the Fix for Our Health System’s Failures
(2d)
The Quiet Battle for the Front Door of Healthcare
(2d)
Chemical & Engineering News
US and French rare earth companies partner in bid to catch up with China
(23h)
Trump administration withdraws on fighting for NIH cap on indirect costs
(1d)
Expansion microscopy tool kit corrects distortion of blown-up cells
(1d)
C&EN weekly chemistry news quiz, April 10
(1d)
An implantable living pharmacy produces drugs in the body
(1d)
Apr 10 Policy Watch: HHS updates criteria for selecting vaccine-committee members
(1d)
Data discovered in surprising places
(1d)
With cash to burn and patent cliffs looming, pharma giants are buying more biotechs
(2d)
Obituary: Thomas L. Penner
(2d)
Obituary: Sanford A. Asher
(2d)
The Pharma Letter
BioNTech and DualityBio’s ADC success
(6h)
MHRA approves Tryngolza for FCS
(7h)
Boehringer hands CT-155 rights to Click in schizophrenia pivot
(1d)
Daiichi taps Imagene to sharpen cancer biomarker discovery
(1d)
Annovis secures financing for buntanetap’s NDA submission
(1d)
Medicines Australia firmly opposes US tariffs on pharmaceuticals
(1d)
Alligator Bioscience links up with Unicancer on mitazalimab
(1d)
Avalyn targets Nasdaq IPO to fund late-stage push
(1d)
Cartherics deepens Catalent alliance to scale CAR-NK manufacturing
(1d)
Boehringer and BioNTech collaborate on SCLC trial of obrixtamig combo
(1d)
Targeted Oncology
Ozekibart Plus Chemo Shows Promising Activity in R/R Ewing Sarcoma
(4w)
Reduced CRS Rates Support Wider Adoption of Bispecifics in Myeloma
(4w)
GLSI-100 Vaccine Shows <1% Annual Recurrence Rate in Phase 3 Breast Cancer Trial
(4w)
Treating Triple Negative Breast Cancer in the Frontline Setting
(4w)
Early Phase Evaluation of Intravesical Erdafitinib in NMIBC
(4w)
Zovegalisib Plus Fulvestrant Shows Durable PFS in PI3Kα-Mutated HR+/HER2− Metastatic Breast Cancer
(4w)
Phase 3 Trial of Eftilagimod Alfa in First-Line NSCLC Halted After Futility Analysis
(4w)
Keeping Bone Health Top of Mind in Androgen Deprivation Therapy
(4w)
Introducing CELMoDs into the Multiple Myeloma Treatment Paradigm
(4w)
Role of Dual Maintenance Remains Uncertain in Multiple Myeloma
(4w)
MedWatch
Avalyn Pharma files for an IPO in the US
(1d)
Life sciences lawyer warns of potential exodus from Denmark after Trump price offensive
(1d)
UBS estimates that Novo Nordisk is approaching the upper half of its sales forecast
(1d)
Danish biotech chairman reaches career pinnacle after billion-dollar acquisition
(1d)
Key employee leaves Novo Nordisk after 36 years
(1d)
Gilead acquires Tubulis for up to USD 5 billion
(1d)
Wegovy pill gains slightly in the US
(1d)
EMA approval gives Wegovy greater flexibility in supplying patients
(1d)
IO Biotech founder after bankruptcy: ”Our work is far from wasted”
(2d)
Study: Weight-loss drugs may help prevent addiction
(2d)
In The Pipeline
Consider the Selfish Ribosome
(1d)
New Bond Formations Just Keep On Coming
(3d)
Ah, Peptides. Where to Begin?
(5d)
A New Opioid Agonist?
(1w)
Say "Chameleonicity" Three Times Fast. Or Read This Post.
(1w)
Right Through the Skull
(1w)
Revving Up LNP Delivery
(2w)
The Latest CAR-T Work
(2w)
Fentanyl's Membrane Behavior
(2w)
Set Phasers to "Kill". No, Not Those Phasers.
(2w)
Pharmaphorum
Senju launches first-in-class dry eye disease drug in Japan
(1d)
Diagnostics lag is holding back new therapies, says study
(1d)
Chinese trial backs base-editing drug for thalassaemia
(1d)
Roche places a $1bn bet on C4T degrader-antibody conjugates
(1d)
Boehringer transfers schizophrenia DTx selling rights to Click
(1d)
Pulmonary fibrosis drug developer Avalyn files IPO
(2d)
NHS risks missing out on independent prescriber benefits
(2d)
AbbVie tries a new approach in 340B programme battle
(2d)
23andMe study explains variable results with obesity drugs
(2d)
Syneron raises $150m for macrocylics, and other financings
(2d)
Drug Discovery Weekly
This week in Drug Discovery (6 – 10 April)
(1d)
Collaboration to advance AAV production enhancers
(1d)
Chemify’s drug discovery platform validated by papers
(1d)
Designing scalable psychedelic therapies for treatment‑resistant depression
(1d)
Oxeia surpasses funding goal for concussion therapy
(1d)
Gene therapy could eradicate tumours in brain cancer
(1d)
Research uncovers previously unknown recessive condition
(2d)
How is the regulatory landscape shaping drug development?
(2d)
Webinar: Overcome the hurdles in ADC discovery
(2d)
AC Immune and Lilly reach agreement on drug collaboration
(3d)
HIT Consultant
Death by a Thousand Vendors: Solera Report Reveals The Hidden Costs of Digital Health
(1d)
Qventus Report: 94% of Healthcare CIOs Say AI Delays Create Competitive Disadvantage
(1d)
The Perioperative AI Reality Check: Why Hospital Tech Fails Without Clinician Co-Design
(1d)
EBSCO Clinical Decisions Report: 80% of Clinicians Trust Evidence-Based AI Tools
(1d)
J.D. Power: Why Medicare Advantage App Usage is Plummeting While Commercial Adoption Soars
(1d)
Amazon Pharmacy Partners with Eli Lilly to Offer Foundayo GLP-1 with Same-Day Delivery
(2d)
Luminai Secures $38M, Inks Enterprise AI Partnership with Cleveland Clinic
(2d)
Click Therapeutics Secures $50M to Commercialize Schizophrenia Digital Therapeutic
(2d)
Talkiatry Launches Talkiatry Connect for Cloud-Based EMR Psychiatric Referrals
(2d)
eClinicalWorks Launches Production Support for CMS ‘Kill the Clipboard’ Initiative
(2d)
Insights: Pink Sheet
US FDA Defends Review Consistency In Second CRL For Replimune’s RP1
(19h)
Plausible Mechanism Case Studies: Why US FDA Guidance Matters
(1d)
Pink Sheet Podcast: Leucovorin’s Resurrection, PhRMA’s Leadership Change
(1d)
Estonia Steps Into EU Race To Accelerate Clinical Trial Approvals
(1d)
Canada’s HTA Agency Launches New Funding To Strengthen Rare Disease Registries And RWD
(1d)
UK-US Trade Deal: Zero Tariffs On UK Exports And Possible MFN Relief For UK
(1d)
India’s High-Stakes Oral Semaglutide Battle And Novo’s ‘SNAC’ Wall
(1d)
US Pharma Tariffs – Exemptions Need More Clarity, Impact Varied
(1d)
China Launches Nationwide Plan For AI-Assisted Drug Regulation
(1d)
Korea On Alert For Medical Product Shortages Amid Middle East Crisis
(1d)
BioXconomy
Beyond Redaction: Governing Confidential Information in an Era of Expaning Transparency
(4d)
Avalyn Pharma eyes IPO to fund Phase III trials of inhaled respiratory drugs
(1d)
Stipple Bio step onto the scene with $100m Series A
(1d)
Rising tides: Neuland appoints CEO to lead firm’s 'aggressive' peptide expansion phase
(2d)
Study reveals 6.7% of global clinical trials affected by Middle East disruption
(2d)
How Bristol Myers Squibb prepared for Medicare price talks
(2d)
340B and Medicaid monitoring in pharma
(2d)
Building a nonprofit pathway for lifesaving gene therapies
(2d)
How FemTech Portugal is building a women’s health ecosystem
(2d)
Jeito banks $1.2bn to support smaller biopharma companies
(2d)
BioCentury
Fibrosis company Avalyn seeks NASDAQ listing amid volatility: Finance Report
(22h)
Stipple: Epitope-level precision for safer cancer therapies
(23h)
Blackstone’s Galakatos on scaling deals with $6.3B fund: ‘Broader, further’
(1d)
Industry shifts FDA from punitive to reward-based America First PDUFA policy
(2d)
Science Spotlight: Altos Labs’ cognition enhancer
(2d)
Front Row with BioCentury: Asia innovation and dealmaking beyond China
(2d)
Biogen strengthens case for BDCA2 as a cutaneous lupus target
(2d)
Tackling translation: The Parker Institute model
(3d)
With €1B fund, Jeito looks for ‘plug-and-play’ biotechs ripe for pharma takeouts
(3d)
Two $1B+ deals in 2Q26’s first week
(3d)
SCRIP
Finance Watch: Replimune Cutting Jobs As FDA Rejects RP1 A Second Time
(22h)
Biopharma IPOs Had Their Best Showing In More Than A Year In Q1
(22h)
Pipeline Watch: Three Approvals And Thirteen Phase III Readouts
(1d)
Top 12 Pharma Companies: Eli Lilly Shoots To The Top, Merck Tumbles
(1d)
Iran War: India’s Supply Chain Shocks, Contract Stress And Spillover Risks
(1d)
MacroGenics Avoids Worst-Case Scenario For Lorigerlimab As US FDA Lifts Trial Hold
(1d)
Sumitomo To Fortify R&D, Pay Off Debt Through $730m Stock Offering
(1d)
Finance Watch: Alternative Funding Agreements Abound, From Small To Large Biopharma
(2d)
Roche And C4 Expand Alliance Into Degrader-Antibody Conjugate Work
(2d)
Assertio Agrees To Buyout By Garda Therapeutics
(2d)